← The SEC Ephemeris: the whole map
Gilead Sciences, Inc. lenacapavir
In the graph: all 4 documents (132 pages).
- Application
- NDA 215973
- Ticker
- GILD
- Product
- lenacapavir
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- February 28, 2022 · February 28, 2022
From FDA letters and SEC filings. Not investment or medical advice.